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ABSTRACT
Although growth factors and chemokines elicit differ-
ent overall effects on cells—growth and chemotaxis,
respectively—and activate distinct classes of cell-surface
receptors, nonetheless, they trigger similar cellular activ-
ities and signaling pathways. The growth factor M-CSF
and the chemokine CXCL12 both stimulate the endocytic
process of macropinocytosis, and both activate the
mechanistic target of rapamycin complex 1 (mTORC1), a
protein complex that regulates cell metabolism. Recent
studies of signaling by M-CSF in macrophages identified a
role for macropinocytosis in the activation of mTORC1, in
which delivery of extracellular amino acids into lysosomes
via macropinocytosis was required for activation of
mTORC1. Here, we analyzed the regulation of macro-
pinosome (MP) formation in response to CXCL12 and
identified 2 roles for macropinocytosis in the activation of
mTORC1. Within 5 min of adding CXCL12, murine macro-
phages increased ruffling, macropinocytosis and amino
acid-dependent activation of mTORC1. Inhibitors of mac-
ropinocytosis blocked activation of mTORC1, and various
isoform-specific inhibitors of type 1 PI3K and protein kinase
C (PKC) showed similar patterns of inhibition of macro-
pinocytosis and mTORC1 activity. However, unlike the
response to M-CSF, Akt phosphorylation (pAkt) in re-
sponse to CXCL12 required the actin cytoskeleton and the
formation of macropinocytic cups. Quantitative fluores-
cence microscopy showed that phosphatidylinositol
(3,4,5)-trisphosphate (PIP3), a product of PI3K and an
upstream activator of Akt, localized to macropinocytic
cups and that pAkt occurred primarily in cups. These
results indicate that CXCL12 activates mTORC1 via 2
mechanisms: 1) that the macropinocytic cup localizes Akt
signaling and 2) that MPs convey extracellular nutrients to
lysosomes. J. Leukoc. Biol. 101: 683–692; 2017.
Introduction
Macropinocytosis is a dynamic endocytic process in which large
vesicles form from actin-rich cell-surface ruffles. It is a common
activity in cells stimulated by growth factors and chemokines and
in cells transformed by oncogenic mutations. Since its discovery
by time-lapse microscopy of macrophages and sarcoma cells [1],
macropinocytosis has been implicated in antigen processing by
phagocytes [2], uptake of bacteria and viruses [3, 4], and cell
growth and cancer [5–8]. MPs internalize nutrients necessary for
anabolic metabolism and may also serve as essential components
of signal transduction.
M-CSF is a hematopoietic growth factor that stimulates
macropinocytosis in BMMs [9]. MP formation begins with Rac1
activation, which triggers formation of actin-rich membrane
ruffles and macropinocytic cups. Class I PI3Ks transiently
synthesize PIP3 and PI(3,4)P2 in the inner leaflet of the cup
membrane, which recruits and activates Akt and PLCg, which
generates DAG, which activates PKC and Ras, leading to closure
of the cup into a MP [10, 11]. The components of a MP
membrane change during intracellular trafficking; the GTPase
Rab5a is exchanged for Rab7 before the MP fuses with the
lysosome [12].
We recently demonstrated that macropinocytosis is required
for M-CSF-induced activation of mTORC1, a key promoter of cell
growth and proliferation in response to growth factors, cytokines,
and amino acids [13, 14]. Growth factor-induced mTORC1
activation requires 2 small GTPases—Rag and Rheb—which are
located on the lysosome and are regulated by amino acids and
growth factors, respectively [15, 16]. MPs formed after M-CSF
stimulation deliver extracellular amino acids into the lysosome,
resulting in Rag activation, a vesicular pathway of mTORC1
activation [7]. Meanwhile, PIP3 or PI(3,4)P2 synthesized in
membranes recruits Akt via its PIP3-binding PH domain, and
membrane-localized Akt is phosphorylated by PDK1. pAkt
inhibits the repressive activity of the TSC1/2 protein complex,
thereby activating Rheb and providing a cytosolic pathway of
mTORC1 activation. Thus, M-CSF activates mTORC1 by 2
coordinated pathways: vesicular and cytosolic [7].
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These studies were initiated as a test of the hypothesis, developed
in our earlier study of growth factor signaling, that MPs are discrete
units of signal transduction to mTORC1. The chemokine CXCL12
binds to the G-protein-coupled receptor CXCR4 to stimulate
chemotaxis in macrophages [17]. It also stimulates macropinocy-
tosis in human hepatocarcinoma cells, HeLa cells, and BMM
[18–21]. Therefore, CXCL12 provides a growth factor-
independent mechanism for inducing MPs and asking if, like
M-CSF, CXCL12-stimulated macropinocytosis can activate
mTORC1 by a vesicular pathway, delivering extracellular amino
acids into lysosomes, and by a cytosolic pathway involving pAkt. To
test this idea, we analyzed the mechanism of MP formation in
BMM in response to CXCL12 and the relationship between
macropinocytosis and activation of mTORC1. We show that
macropinocytosis is necessary for activation of mTORC1 by
CXCL12 in macrophages and that different PI3K p110 isoforms
contribute to MP formation, pAkt, and mTORC1 activation. Unlike
M-CSF-induced activation of mTORC1, the cytosolic pathway
leading to pAkt, induced by CXCL12, required membrane ruffling
and macropinocytic cup formation. These findings indicate 2




DMEM (low glucose; 11885), DPBS, HBSS, EIPA, and FITC-Dextran MW
70,000 (FDx70) were purchased from Thermo Fisher Scientific (Waltham,
MA, USA). CXCL12 was from PeproTech (Rocky Hill, NJ, USA). Mouse
M-CSF was from R&D Systems (Minneapolis, MN, USA). MK2206 was from
ApexBio (Boston, MA, USA). Calphostin C was from EMD Millipore
(Billerica, MA, USA). Blebbistatin, staurosporine, and Gö6976 were from
Abcam (Cambridge, MA, USA). Jasplakinolide was from Enzo Life Sciences
(Farmingdale, NY, USA). A66, TGX221, IC87114, and AS252424 were from
Symansis Cell Signaling Sciences (Temecula, CA, USA). LY294002, anti-S6K
(2708), anti-pS6K (Thr389; 9234), anti-Akt (9272), anti-pAkt (Thr308;
4056), anti-Erk1/2 (4695), anti-pErk1/2 (Thr202/Tyr204; 4376), anti-TSC2
(4308), anti-pTSC2 (3617), anti-4EBP1 (9644), anti-p4EBP1 (Thr37/46;
2855), anti-Akt (2920), and anti-pAkt (Thr308; 2965) antibodies were from
Cell Signaling Technology (Danvers, MA, USA). HRP-conjugated goat
anti-rabbit IgG was from GE Healthcare (Pittsburgh, PA, USA). Anti-rabbit
Alexa-488 and anti-mouse Alexa-594 antibodies were used as secondary
antibodies (Thermo Fisher Scientific).
Cells
BMMs were generated from femurs of C57BL/6J mice and cultured for 6–7 d,
as described previously [10]. All animal-related procedures were approved by
the University of Michigan Committee on Use and Care of Animals.
MP assay and mTORC1 assay
The number of induced MPs per BMM was quantified, as described previously
[7]. FDx70 (0.5 mg/ml) was added together with CXCL12 (50 nM) or M-CSF
(6.9 nM or 0.14 nM). After 5 or 15 min, uningested dye was removed by gentle
washing with DPBS, and cells were fixed for 30 min at 37°C with fixation
buffer A (20 mM HEPES, pH 7.4, 2% paraformaldehyde, 4.5% sucrose,
70 mM NaCl, 10 mM KCl, 10 mM MgCl2, 2 mM EGTA, 70 mM lysine-HCl,
10 mM sodium periodate), followed by rinsing in DPBS and microscopic
observation. More than 25 cells were observed for each assay. Merged images
of phase-contrast and background-subtracted FDx70 images were generated
using MetaMorph (Molecular Devices, Sunnyvale, CA, USA), and the
number of induced MPs per cell was determined by counting FDx-positive
vesicles. From 3 independent experiments, the number of induced MPs per
cell under each condition was calculated and presented as mean and SEM.
One-way ANOVA and Tukey’s tests were used for statistical analysis. To
measure mTORC1 and related activities, pS6K, pAkt, pERK, p4EBP1, and
pTSC2 were analyzed by Western blotting. BMMs were stimulated by buffer
(control), CXCL12 (50 or 200 nM), or M-CSF (6.9 or 0.14 nM) for 5 min and
lysed for 10 min in ice-cold lysis buffer [40 mM HEPES, pH 7.5, 120 mM
NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, 50 mM
NaF, 1.5 mM Na3VO4, 0.3% CHAPS, and a mixture of protease inhibitors
(Roche Applied Science, Indianapolis, IN, USA)]. Lysates were centrifuged
for 15 min at 13,000 g, and the supernatant was mixed with 43 SDS buffer
and boiled for 5 min. Two or more independent experiments were
performed to confirm the results of pilot experiments.
Cell treatments
For both MP and mTORC1 assays, BMMs were cultured in DMEM
(low glucose) without FBS overnight. For inhibitor treatments, cells were
pretreated with LY294002 (50 mM), MK2206 (2 mM), or EIPA (25 mM) for
30 min in DMEM (low glucose). A combination of blebbistatin (75 mM for
35 min) and jasplakinolide (1 mM for 15 min) was also used. For p110
isoform inhibitor experiments, cells were pretreated for 30 min with A66
(3 mM), TGX221 (0.5 mM), AS252424 (2 mM), and/or IC87114 (2 mM)
before 5 min CXCL12 stimulation [7, 22, 23], followed by observation or
fixation. To inhibit PKC, cells were pretreated with staurosporine (100 mM)
or Gö6976 (2 or 5 mM) for 30 min or with calphostin C (200 nM) for 50 min
in a CO2 incubator before transfer into a biologic safety cabinet for light
activation for another 10 min [7, 24]. For amino acid depletion assays, cells
were cultured in HBSS instead of DMEM for 30 min before stimulation with
CXCL12. Images were captured on a Nikon Eclipse TE-300 inverted
microscope with a 603 numerical aperture 1.4 oil-immersion PlanApo
objective lens (Nikon, Tokyo, Japan) and recorded on MetaMorph software
using a Photometrics CoolSNAP HQ CCD camera (Photometrics, Tucson,
AZ, USA).
Quantitative membrane-ruffling assay
Time-lapse images were captured every 20 s, and montage images were made
using MetaMorph. After capturing time-lapse phase-contrast images, the
membrane-ruffling area was defined by tracing phase-dark areas inside of the
cell. Threshold binary images indicating the phase-dark areas were made with
the “Binary Operations” command in MetaMorph. To quantify the area of
membrane ruffling, first, a square region that included the entire cell profile
throughout the image series was defined using the phase-contrast images. The
square was then transferred from the phase-contrast image stack to the binary
image montage (location relative to the cell was maintained), allowing
measurement of the total binary area of membrane ruffling within the defined
square region. The ruffling area at each time point was calculated relative to
the area at the time when CXCL12 was added (t = 0 min). Student’s t test was
used for statistical analysis.
Ratio imaging
The plasmids pECFP-N1, pmCitrine-C1, and pAkt-PH-mCitrine were used for
the expression of CFP, YFP, and YFP-Akt-PH, respectively [11]. Plasmids were
transfected into BMM using the Amaxa Mouse Macrophage Nucleofector kit
(Lonza, Cologne, Germany), according to the manufacturer’s protocol. As a
control experiment, free mCitrine (as YFP) and free CFP were expressed in
BMM. Phase-contrast, YFP, and CFP images of live BMMs were captured every
20 s for 10 min. Ratio images of YFP-Akt-PH relative to CFP were generated, as
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described previously [11]. The ratio image corrects for variations in optical path
length as a result of cell shape. The comparison of phase-contrast and ratio
images allowed us to relate the morphologic process of macropinocytosis with
the timing of the YFP-Akt-PH association with the plasma membrane.
Immunofluorescence staining of Akt and pAkt
Immunofluorescence staining of Akt and pAkt was carried out by following
the established method reported previously [25], with several modifications.
BMMs, treated for 1 or 3 min with or without CXCL12, were fixed at room
temperature for 10 min with fixation buffer B (4% paraformaldehyde,
20 mM HEPES, pH 7.4, 70 mM NaCl, 10 mM KCl, 10 mM MgCl2, 2 mM
EGTA, 70 mM lysine-HCl, 10 mM sodium periodate). Cells were washed
3 times with TBS (50 mM Tris, 150 mM NaCl, pH 7.6), permeabilized in
freshly prepared 0.2% saponin in TBS (w/v) for 15 min at room
temperature, and then incubated in 1% BSA in TBST (w/v) for 30 min at
room temperature. Anti-Akt (2920; Cell Signaling Technology) and anti-
pAkt (Thr308; 2965; Cell Signaling Technology) antibodies were diluted at
1:50 in blocking buffer and incubated with the samples for 2 h at room
temperature as primary antibody treatment. Samples were washed with
TBST for 3 3 10 min. Anti-rabbit Alexa 488 and anti-mouse Alexa 594
antibodies were diluted at 1:200 in blocking buffer and incubated with the
samples for 1.5 h at room temperature as secondary antibody treatment.
Samples were washed with TBST for 3 3 5 min and with distilled water for
5 min before mounting for microscopic observation.
Quantitative pAkt/Akt assay
With the use of MetaMorph image analysis software, Akt (572–632) and
pAkt (500–535) images were corrected for shade, bias, and background [26].
A binary image map was then produced from the corrected Akt (de-
nominator) image. The corrected Akt images and binary images were
combined using the “Logical AND” command (AND Akt image), and the
corrected pAkt image was divided by the AND Akt image, multiplied by 100.
These ratio images were analyzed to quantify the total intensity of pAkt/Akt
signaling in 10 or more cells. The ratio image was thresholded to exclude
background area, and cellular regions were selected manually. With the use of
the “Region Measurements” command, the pAkt/Akt Integrated Intensity
and Threshold Area for each cell were logged to Excel. In Excel, integrated
intensities were divided by the threshold areas to yield relative intensities.
Student’s t test was applied to the results of 3 independent experiments.
Online supplemental material
Five Supplemental figures support the conclusions of this paper.
RESULTS
CXCL12 elicits membrane ruffles and MPs in BMMs
The response of BMM to CXCL12 resembled their response to
M-CSF. Time-lapse microscopy of cells stimulated with CXCL12
showed vigorous membrane ruffling and MP formation (Fig. 1A).
Ruffling increased immediately after CXCL12 treatment and
continued for 3 min following addition of CXCL12 (Fig. 1B and
C). Ruffles changed into macropinocytic cups, which closed after
60 s. By 200 s, the internalization of a phase-bright MP was
complete (Fig. 1D). Quantification showed that in 5 min
following CXCL12 addition, BMM formed an average of 2.06
MPs per cell. This number decreased slightly by 15 min,
suggesting that macropinocytosis was induced within 5 min
and that MPs began the maturation process within the following
10 min (Fig. 1E and F).
Figure 1. CXCL12 induces membrane ruffling and macropinocytosis in BMMs. (A) CXCL12 treatment induced membrane ruffles and MPs (arrows).
Times after addition of CXCL12 are indicated at top left (minutes:seconds). Original scale bar, 10 mm. (B) Quantification of membrane ruffling
induced by CXCL12. The area of membrane ruffling was defined as phase-dark patches in the phase-contrast image. Time after addition of CXCL12 is
indicated [upper, top right (minutes:seconds)]. Original scale bars, 10 mm. (C) Quantitative analysis of ruffling area with (n = 7; squares) and without
(n = 8; crosses) CXCL12. The area of membrane ruffling was measured from the binary images (as shown in B). The ruffling areas increased
significantly after CXCL12 stimulation (*P , 0.05). (D) Montage image of MP formation in the cell shown in A. MP formation began with membrane
ruffling (t = 260 to +0 s). A C-shaped ruffle (t = +0 s) curved into an O-shaped cup (t = +60 s) and then pinched shut (from t = +200 s). Original scale
bar, 2 mm. (E) Phase-contrast images of BMM incubated 5 min in the presence of FDx70 without (Control) or with (+CXCL12) CXCL12. The vesicles
labeled with red overlay indicate FDx70-positive MPs. Original scale bars, 10 mm. (F) CXCL12 induces macropinocytosis within 5 min. BMMs were
treated with CXCL12 and FDx70 for the indicated times and then were fixed and scored for FDx70-positive MPs. More than 75 cells from 3
independent experiments were observed. *P , 0.05. N.S., No significant difference.
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Roles for PI3K p110 isoforms in MP formation
Class I PI3Ks are heterodimers consisting of a p85 regulatory
subunit and a p110 catalytic subunit. p110a and p110b are
expressed ubiquitously, whereas p110d and p110g are mostly
expressed in leukocytes [27]. We investigated the involvement of
the different class I PI3K isoforms in CXCL12-induced MP
formation using isoform-specific inhibitors. The general PI3K
inhibitor LY294002 inhibited CXCL12-induced macropinocytosis
(Supplemental Fig. 1). Independent inhibition of each p110
isoform resulted in partial inhibition of MP formation (Fig. 2).
Combined inhibitor treatments of A66 (p110a inhibitor)/TGX221
(p110b inhibitor) and AS252424 (p110g inhibitor)/IC87114
(p110d inhibitor) yielded nearly complete inhibition of macro-
pinocytosis. These results indicate that CXCL12-induced
macropinocytosis is differentially regulated by class I PI3Ks.
p110a and p110g inhibitors attenuate pAkt and pS6K
To determine which isoforms are directly involved in pAkt and
pS6K in response to CXCL12, we performed Western blot
analyses of BMM treated with p110 isoform-specific inhibitors.
A 5 min CXCL12 treatment was sufficient to induce pAkt and
pS6K (Fig. 3). Levels of pAkt and pS6K were decreased
significantly by the p110g inhibitor AS252424 and the p110a
inhibitor A66 but not by p110d inhibitor IC87114 or the p110b
inhibitor TGX221 (Fig. 3). A combination of p110b and p110d
inhibitors did not affect CXCL12-induced pAkt (Supplemental
Fig. 2), indicating that the p110g and p110a isoforms perform
more significant roles than the p110d and p110b isoforms in
CXCL12-induced pAkt and mTORC1 activation in macrophages.
CXCL12-stimulated mTORC1 activation requires
extracellular amino acids
To investigate the effect of ingested amino acids by
CXCL12-induced macropinocytosis on mTORC1 activation,
BMMs were stimulated for 5 min with CXCL12 in amino acid-free
(HBSS) or amino acid-rich (DMEM) conditions (Fig. 4). Whereas
cells in the no-stimulus control groups produced few MPs, cells
stimulated with CXCL12 in either HBSS or DMEM produced
significantly more MPs (Fig. 4A and B). However, Western blot
analysis of cell lysates from each condition showed that pAkt and
pTSC2 were apparent in both HBSS and DMEM, but pS6K
increased in the DMEM condition only (Fig. 4B). pERK was
increased with or without amino acids, as has been reported in
other cells [28–31] (Fig. 4B). Thus, CXCL12 induced macro-
pinocytosis and pAkt and pTSC2 in the presence or absence of
amino acids, yet pS6K required amino acids.
Akt inhibitor blocks CXCL12-induced mTORC1
activation but not macropinocytosis
Given that p110 inhibitors block macropinocytosis (Fig. 2), we
hypothesized that Akt contributes to CXCL12-induced MP
formation. To test this, we measured the effects of the
Figure 2. PI3K p110 isoform inhibitors inhibit macropinocytosis.
(A) Fixed-cell imaging of MP formation following treatment with
inhibitors. FDx-positive vesicles (MPs) are labeled with red overlay.
CXCL12 treatment induced MP formation. Compared with the +CXCL12
sample (CXCL12), cells treated with a combination of p110d and p110g
inhibitors (CXCL12+g/d) or a combination of p110a and p110b
inhibitors (CXCL12+a/b) contained few or no MPs. Original scale
bars, 10 mm. (B) Quantification of the MP assay. Partial inhibition of
pinocytosis was evident when cells were treated with the p110g inhibitor
(AS252424), p110d inhibitor (IC87114), p110a inhibitor (A66), or
p110b inhibitor (TGX221) independently. When used in combination,
however, the cocktail of p110g/d inhibitors or p110a/b inhibitors
yielded nearly complete inhibition of macropinocytosis (*P , 0.05).
More than 75 cells from 3 independent experiments were observed.
Figure 3. p110g and p110a inhibitors attenuated
CXCL12-induced pAkt and pS6K. (A) The p110g
inhibitor (AS252424), but not the p110d inhibitor
(IC87114), blocked pAkt and pS6K. (B) The
p110a inhibitor (A66), but not the p110b in-
hibitor (TGX221), blocked CXCL12-induced pAkt
and pS6K.
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Akt-specific inhibitor MK2206 [32] on macropinocytosis and
growth factor signaling in response to CXCL12. The inhibitor did
not significantly reduce macropinocytosis (Fig. 5A and B) but
reduced pAkt, pTSC2, and pS6K without affecting pERK (Fig. 5B),
similar to what was observed after stimulation with M-CSF [7].
Therefore, although Akt is not required for macropinocytosis, it
activates the TSC pathway in response to CXCL12 stimulation.
Macropinocytosis-specific inhibitors attenuate
CXCL12-induced mTORC1 activation
Based on the role of macropinocytosis in mTORC1 activation by
M-CSF, we hypothesized that the morphologic changes triggered
by CXCL12 treatment were required for mTORC1 activation but
not for pAkt. To test this, we used the cytoskeleton inhibitors J/B
and the macropinocytosis inhibitor EIPA to block CXCL12-
induced membrane ruffling and macropinocytosis (Fig. 6). Both
treatments inhibited pS6K, but in contrast to what was observed
for M-CSF [7], they also attenuated CXCL12-induced pAkt and
pTSC2 (Fig. 6B and C, and Supplemental Fig. 3). Additionally,
whereas J/B treatments inhibited pS6K and pERK (Fig. 6B),
EIPA blocked pS6K but not pERK. Although EIPA is not entirely
specific for macropinocytosis and may interfere more generally
with activation of Rac [33], these data suggest that CXCL12-
induced ruffles and cups trigger the Akt pathway. J/B and EIPA
also blocked p4EBP1, another target of mTORC1 (Fig. 6B and
C). Collectively, these data strongly suggest that CXCL12-induced
macropinocytosis also contributes to the cytosolic (Akt/TSC2)
pathway for activation of mTORC1.
In considering why pAkt, in response to CXCL12 (50 nM), was
sensitive to inhibitors of macropinocytosis, we noticed that the
magnitude of signals elicited by M-CSF (6.9 nM) was greater than
that elicited by CXCL12 (50 nM; Supplemental Fig. 3A). We
hypothesized that signaling by lower concentrations of M-CSF
may also require structure-based signal amplification for activa-
tion of Akt. To investigate further the relationship between
macropinocytosis and pAkt, we measured the effect of EIPA on
signaling in response to high (6.9 nM) and low (0.14 nM)
concentrations of M-CSF (Supplemental Fig. 3B). As reported
previously [7], pAkt and pTSC2, in response to high concentra-
tions of M-CSF, were not blocked by EIPA treatment. However, in
response to low concentrations of M-CSF, pAkt and pS6K, but not
pERK, were attenuated by EIPA. The low level of pAkt elicited by
CXCL12 was not a consequence of using submaximal concen-
trations, as increasing the CXCL12 concentration to 200 nM did
not affect pAkt levels. pAkt induced by 200 nM CXCL12 was also
attenuated by EIPA (Supplemental Fig. 3A). These results
indicate that maximal M-CSF concentrations trigger sufficiently
strong PI3K signaling to induce cup-independent pAkt, whereas
0.14 nM M-CSF and CXCL12 require the cup structure for signal
amplification.
PKC inhibitors block CXCL12-induced
macropinocytosis and mTORC1 activation
PKC is required for macropinocytosis in several cell types [34].
We investigated the role of PKCs in CXCL12-induced macro-
pinocytosis and mTORC1 activation using the PKC inhibitors
staurosporine, calphostin C, and Gö6976, which have been
shown previously to inhibit macropinocytosis [7, 35, 36].
Staurosporine inhibited macropinocytosis and pAkt and pS6K
(Fig. 7A and B). In calphostin C, cells induced membrane ruffles
and cup-like structures, but MP closure was blocked (Fig. 7A and
C), suggesting that calphostin C blocked CXCL12-induced
Figure 4. Depletion of extracellular amino acids diminishes
CXCL12-induced mTORC1activation without inhibiting
macropinocytosis. (A) Phase-contrast images of BMM treated with
CXCL12 and FDx70 for 5 min in HBSS (no amino acids) versus DMEM
(physiologic levels of amino acids). Fluorescence microscopy showed many
FDx70-positive MPs (red overlay) both in HBSS and in DMEM. Original
scale bars, 10 mm. (B) The bar graph displays quantitative analysis of
CXCL12-induced macropinocytosis. Western blot analysis showed no pS6K
after CXCL12 treatment in HBSS but increased pS6K after CXCL12
treatment in DMEM. More than 75 cells from 3 independent experiments
were observed. *P , 0.05. N.S., No significant difference.
Pacitto et al. CXCL12 stimulates mTORC1 via macropinocytosis
www.jleukbio.org Volume 101, March 2017 Journal of Leukocyte Biology 687
macropinocytosis by inhibiting cup closure. Western blot analysis
showed that whereas pAkt, pTSC2, and pERK levels were not
reduced by calphostin C, pS6K decreased slightly (Fig. 7C). This
suggests that the inhibitor reduced the vesicular pathway to
mTORC1 but not the cytosolic pathway. Likewise, Gö6976
inhibited MP formation but not the formation of membrane
ruffles and cup-like structures (Fig. 7A and D). Gö6976 also
attenuated pS6K without inhibiting pAkt, pTSC2, or pERK
Figure 6. Inhibition of membrane ruffling and macropinocytic cup
formation attenuates CXCL12-induced pAkt and mTORC1 activation.
(A) Phase-contrast images of BMM treated with FDx70 and CXCL12
for 5 min without inhibitor (CXCL12), with a combination of
cytoskeleton inhibitors J/.B (CXCL12+J/B), or with macropinocytosis
inhibitor EIPA (CXCL12+EIPA). FDx70 fluorescent images (red signal)
overlay the phase-contrast images. Red-filled vesicles are MPs. J/B and
EIPA blocked CXCL12-induced membrane ruffling and macropinocy-
tosis. Original scale bars, 10 mm. (B) MP formation after no treatment,
CXCL12, and CXCL12 with J/B. J/B significantly decreased the average
number of MPs per cell. Western blot analysis shows a decrease in
pAkt, pS6K, p4EBP1, pTSC2, and pERK in J/B + CXCL12-treated cells
compared with the CXCL12 (no inhibitor) sample. (C) EIPA signifi-
cantly decreased the average number of MPs per cell. Western blot
analysis shows a decrease in pAkt, pS6K, p4EBP1, and pTSC2 in the
EIPA + CXCL12 treatment compared with the CXCL12 (no inhibitor)
condition. More than 75 cells from 3 independent experiments were
observed. *P , 0.05.
Figure 5. PI3K regulates CXCL12-induced macropinocytosis independent
of Akt function. (A) Phase-contrast images of BMM treated with
FDx70 and CXCL12 for 5 min without inhibitor (CXCL12) or with
(CXCL12+MK) the Akt inhibitor MK2206. FDx70 fluorescent images
(red signal) overlay the phase-contrast images. CXCL12-induced macro-
pinocytosis was not inhibited by MK2206. Original scale bar, 10 mm.
(B, upper) The bar graph displays the quantified results of MP assays
with no treatment, CXCL12 treatment, and CXCL12 treatment with
MK2206. (Lower) Western blot analysis shows that MK2206 completely
blocked pAkt and inhibited pTSC2 and pS6K compared with the
positive stimulus condition (+CXCL12). CXCL12-induced pERK was
not affected. More than 75 cells from 3 independent experiments were
observed. *P , 0.05. N.S., No significant difference.
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(Fig. 7D). The specificity of Gö6976 for PKCa and -b [37]
suggests that these PKC isoforms are necessary for macro-
pinocytic cup closure and pS6K. Staurosporine and calphostin C
weakly blocked p4EBP1, another reporter of mTORC1 activity
(Fig. 7B and C), and Gö6976 completely blocked p4EBP1 (Fig.
7D). These results suggest that different PKC isoforms serve
distinct roles in the mechanism of pAkt and macropinocytosis.
Akt is phosphorylated within macropinocytic cups
Activated class I PI3Ks generate PIP3 and PI(3,4)P2 at the plasma
membrane. Akt recruited via its PH domain to these
phosphoinositides is directly phosphorylated at threonine 308 by
PDK1 [38, 39] within 5 min of CXCL12 treatment. By expressing
a fluorescent protein-tagged PH domain of Akt in BMM, we
inferred the distributions of Akt by monitoring PIP3 and PI(3,4)
P2 distributions in live cells. Ratiometric imaging showed that
YFP-Akt-PH was recruited to membrane ruffles shortly after
addition of CXCL12 (Fig 8A; +0 to + 80 s). Once membrane
ruffles changed to macropinocytic cups, YFP-Akt-PH accumu-
lated transiently in the cup structures (Fig. 8A; +120 to +220 s), as
observed previously in Dictyostelium [40], EGF-stimulated A431
cells [41], and M-CSF-stimulated BMM [11]. As a negative
control, we observed cells expressing free CFP and free YFP and
confirmed that the ratiometric analysis yielded uniform images
(Supplemental Fig. 4). Therefore, CXCL12-activated class I PI3Ks
generated PIP3 and PI(3,4)P2 in ruffles and cups, and the
dynamics of Akt-PH suggested that Akt itself was recruited to and
phosphorylated at ruffles and cups.
To localize sites of pAkt directly, we used quantitative
immunofluorescence microscopy to localize Akt and pAkt
(Thr308). In control experiments, we analyzed the intensities of
pAkt and Akt labeling in unstimulated cells versus CXCL12-
treated macrophages (Supplemental Fig. 4). The relative in-
tensities of pAkt to Akt signaling in the CXCL12-stimulated
Figure 7. Inhibition of PKC attenuates CXCL12-
induced macropinocytosis and pS6K. (A) Phase-
contrast images of BMM treated with FDx70 and
CXCL12 for 5 min without inhibitors (CXCL12),
with staurosporine (CXCL12+Stauro), calphostin
C (CXCL12+CalC), or Gö6976 (CXCL12+Go).
FDx70 fluorescent images (red signal) overlay the
phase-contrast images; red-filled vesicles are MPs
induced by the experimental conditions.
Staurosporine blocked CXCL12-induced mem-
brane ruffling and macropinocytosis. Calphostin C
and Gö6976 blocked macropinocytosis but not
macropinocytic cup formation (white arrowheads).
Original scale bars, 10 mm. (B) Staurosporine
significantly decreased the average number of
CXCL12-induced MPs per cell and inhibited pAkt,
pS6K, pTSC2, and pERK. (C) Calphostin C
significantly decreased the average number of MPs
per cell. Western blot analysis shows that pAkt,
pTSC2, and pERK, after CXCL12 treatment, was
unaffected by calphostin C, and calphostin C
inhibited pS6K and induced a slight decrease in
p4EBP1. (D) Gö6976 significantly decreased the
average number of MPs per cell. Western blot
analysis showed that pAkt, pTSC2, and pERK, after
CXCL12 treatment, with and without Gö6976,
were equivalent, whereas pS6K and p4EBP1 were
decreased. More than 75 cells from 3 independent
experiments were observed. *P , 0.05.
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samples increased 6-fold relative to the negative control samples,
consistent with the Western blot data showing CXCL12-induced
pAkt (Supplemental Fig. 4). Comparison of the ratio and
phase-contrast images allowed us to localize sites of pAkt. The
relative intensities of pAkt to Akt were highest in membrane
ruffles or macropinocytic cups (Fig. 8B; phase and pAkt/Akt).
Comparison of phase-contrast and pAkt images also showed
strong pAkt signaling in cups (Fig. 8B; phase and pAkt). The
results were consistent with the ratiometric imaging of Akt-PH in
live BMM. Therefore, Akt is recruited to and phosphorylated at
the cup structures within 3 min of CXCL12 treatment.
DISCUSSION
With the analysis of the role of macropinocytosis in signaling by
CXCL12, this study identified a novel role for macropinocytic
cups in the activation of Akt and mTORC1. Previous studies
determined that 2 pathways are required to activate mTORC1 in
response to growth factors: a vesicular pathway mediated by
macropinocytosis and a macropinocytosis-independent cytosolic
pathway comprised of Akt, TSC1/2, and Rheb [7]. The present
study shows that activation of mTORC1 by CXCL12 also requires
macropinocytosis but that the cytosolic pathway is not indepen-
dent of macropinocytosis. pAkt and pTSC2 require formation of
ruffles and macropinocytic cups. This identifies a second
essential role for MPs in signal transduction.
CXCL12 and M-CSF used similar signaling mechanisms for MP
formation and signaling to mTORC1 in BMM. Like M-CSF,
CXCL12 induced membrane ruffles within 1 min, and ruffles
closed to form MPs within the next 4 min (Fig. 1). Class I PI3Ks
and PKCs were necessary for MP formation (Figs. 2 and 7).
Additionally, fluorescent live-cell imaging and immunofluores-
cent staining of cells stimulated by CXCL12 showed that Akt was
recruited to and phosphorylated at membrane ruffles and
macropinocytic cups (Fig. 8). However, unlike signaling to
mTORC1 by M-CSF, CXCL12-induced pAkt was inhibited by the
macropinocytosis-specific inhibitors EIPA and J/B (Fig. 6). Thus,
MP formation and signaling to mTORC1 were identical in
response to M-CSF and CXCL12, except that pAkt in response to
CXCL12 was sensitive to EIPA and JB.
How might pAkt, in response to M-CSF and CXCL12, be
differentially dependent on macropinocytosis? We suggest that
the difference is a result of the different magnitudes of signals
generated by the 2 ligands. Our previous studies of
M-CSF-stimulated BMM showed that pAkt and pTSC2 were not
blocked by the macropinocytosis inhibitor EIPA or by J/B [7]. In
this study, we show that a lower concentration of M-CSF
(0.14 nM) was sufficient to induce macropinocytosis and pAkt in
BMM and that both of these activities were blocked by EIPA
(Supplemental Fig. 3B), similar to what was observed in CXCL12-
stimulated BMM. Interestingly, high concentrations of M-CSF
(5 min, 6.9 nM) induced a stronger pAkt response than did
CXCL12 (Supplemental Fig. 3A). With the increase of CXCL12
concentrations from 50 to 200 nM, concentrations well above the
KD (dissociation constant) for CXCL12 binding to CXCR4
(2 nM) [42] did not increase the level of pAkt, and pAkt, in
response to 50 and 200 nM CXCL12, was similarly attenuated by
EIPA (Supplemental Fig. 3A). Thus, we propose that high M-CSF
concentrations can induce actin-independent pAkt, whereas lower
concentrations of M-CSF (0.14 nM) and CXCL12 elicit weak
responses that require the cup structure for signal amplification
and pAkt. The PKC inhibitor experiments support this idea.
Whereas calphostin C and Gö6976 arrested macropinocytosis at
the stage of macropinocytic cup closure, cup structures were
entirely absent in staurosporine-treated cells (Fig. 7A). Western
blot analysis showed that calphostin C and Gö6976 did not inhibit
CXCL12-induced pAkt, yet staurosporine did (Fig. 7B–D). Thus,
pAkt correlated with the ability to form macropinocytic cups and
Figure 8. CXCL12-induced membrane ruffles and
macropinocytic cups activate Akt. (A) BMMs
expressing YFP-Akt-PH and CFP were imaged
during CXCL12-stimulated macropinocytosis, and
ratio images (YFP/CFP) were processed. The
numbers at the top right in each frame indicate
time following addition of CXCL12 (seconds).
Red and white arrowheads indicate macropino-
cytic cups and corresponding YFP-Akt-PH signal,
respectively. YFP-Akt-PH localized at lamellipodia
and membrane ruffles (t = +0 to t = +80) then
accumulated in macropinocytic cups (t = +120 to
t = +220 s). Color bar indicates relative value of
ratio intensities. Original scale bars, 3 mm. (B)
Immunofluorescent staining of pAkt (Thr308)
and Akt demonstrates that Akt was phosphory-
lated at the cup structure (arrowheads indicate
macropinocytic cup) in a cell fixed 1 min after
addition of CXCL12. Comparison of the phase-
contrast image (phase) and the ratio image
(pAkt/Akt) displays a strong ratio value at the
macropinocytic cup. Color bar indicates relative
value of ratio intensities. Original scale bar, 5 mm.
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indicated that morphologic changes in the plasma membrane are
required for signal amplification leading to pAkt.
Given that both M-CSF and CXCL12 regulate macropinocy-
tosis to activate mTORC1, these 2 ligands may induce identical
physiologic responses in the macrophage. CXCL12 and its
receptor CXCR4 are overexpressed in many types of cancer
[43–45]. Both M-CSF and CXCL12 elicit functions of the
macrophage that promote breast cancer metastasis [46–49].
Macrophages act as tumor suppressors in a cancer-initiated
inflammatory response. However, once tumors are established,
macrophage function switches to tumor promotion (TAMs)
[48, 49]. TAMs promote the migration and invasion of breast
cancer cells via a paracrine loop between the EGF, secreted from
TAMs, and M-CSF, secreted from tumor cells [50, 51]. EGF
stimulation increases the invasive capability and motility of
cancer cells [52]. M-CSF stimulation supports the migration of
TAMs and the secretion of EGF via Wiskott-Aldrich syndrome
protein [52]. It has been suggested that among M-CSF-stimulated
macrophages in a progressing tumor, increased levels of CXCL12
may increase EGF secretion [46–48]. Thus, as CXCL12 can
enhance effects of M-CSF in TAMs, we suggest that their common
mechanism of signaling to mTORC1 via macropinocytosis may
underlie that enhancement.
In summary, CXCL12-induced mTORC1 activation is
regulated by macropinocytosis via 2 mechanisms (Fig. 9). First,
as in the case of M-CSF, amino acid trafficking to lysosomes
by macropinocytosis is required for mTORC1 activation.
Second, macropinocytic cups serve as platforms for pAkt.
This cup dependence of pAkt is likely a result of the low level
of stimulation by CXCL12 compared with M-CSF.
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